

Stanford

Alison Holmes Tisch, MSN, RN, ANP-BC, AOCNP

Professional Overview

BIO

Alison Holmes Tisch, MSN, RN, ANP-BC, AOCNP is an Adult Oncology Certified Nurse Practitioner who specializes in treatment and symptom management for individuals who are living with lung cancer, thymic cancer or mesothelioma. She has practiced in the department of Thoracic Oncology at Stanford Healthcare for more than 8 years and is passionate about supporting individuals and their families during challenging times and ensuring state of the art care with clinical trials, standard treatment options and supportive care and symptom management.

CLINICAL FOCUS

- Nurse Practitioner
- Clinical Operations Manager

PROFESSIONAL EDUCATION

- Professional Education: Yale School of Nursing (2011) CT
- BA, Tufts University , Biochemistry (2005)
- Board Certification: Nurse Practitioner, Oncology Nursing Certification Corp (2012)

Scientific Focus

PUBLICATIONS

- **Pruritus as a Paraneoplastic Symptom of Thymoma** *JOURNAL OF THORACIC ONCOLOGY*
Padda, S. K., Shrager, J. B., Riess, J. W., Pagtama, J. Y., Tisch, A. J., Kwong, B. Y., Liang, Y., Schwartz, E. J., Loo, B. W., Neal, J. W., Hardy, R., Wakelee, H. A.
2015; 10 (11): E110-E112
- **Factors associated with depressive symptoms in cancer family caregivers of patients receiving chemotherapy** *SUPPORTIVE CARE IN CANCER*
Williams, A., Holmes, A. J., Dixon, J., McCorkle, R.
2013; 21 (9): 2387–94
- **Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex** *HUMAN GENETICS*
Qin, W., Kozlowski, P., Taillon, B. E., Bouffard, P., Holmes, A. J., Janne, P., Camposano, S., Thiele, E., Franz, D., Kwiatkowski, D. J.
2010; 127 (5): 573–82
- **Lung Adenocarcinoma with EGFR Amplification Has Distinct Clinicopathologic and Molecular Features in Never-Smokers** *CANCER RESEARCH*
Sholl, L. M., Yeap, B. Y., Iafrate, A., Holmes-Tisch, A. J., Chou, Y., Wu, M., Goan, Y., Su, L., Benedettini, E., Yu, J., Loda, M., Jaenne, P. A., Christiani, et al
2009; 69 (21): 8341–48
- **Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer** *JOURNAL OF THORACIC ONCOLOGY*

- Park, S., Holmes-Tisch, A. J., Cho, E., Shim, Y., Kim, J., Kim, H., Lee, J., Park, Y., Ahn, J., Park, K., Jaenne, P. A., Ahn, M.
2009; 4 (7): 809–15
- **Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers** *CLINICAL CANCER RESEARCH*
Yonesaka, K., Zejnullahu, K., Lindeman, N., Homes, A. J., Jackman, D. M., Zhao, F., Rogers, A. M., Johnson, B. E., Jaenne, P. A.
2008; 14 (21): 6963–73
 - **EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer** *CLINICAL CANCER RESEARCH*
Koivunen, J. P., Mermel, C., Zejnullahu, K., Murphy, C., Lifshits, E., Holmes, A. J., Choi, H., Kim, J., Chiang, D., Thomas, R., Lee, J., Richards, W. G., Sugarbaker, et al
2008; 14 (13): 4275–83
 - **Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?**
Ahn, M., Park, B., Ahn, J., Kim, S., Kim, H., Lee, J., Kang, J., Cho, J., Song, H., Park, S., Sohn, C., Shin, S., Choi, et al
AMER ASSOC CANCER RESEARCH.2008: 3860–66
 - **Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-akt-positive or never smoker patients with advanced non-small-cell lung cancer: The ONCOBELL trial** *JOURNAL OF CLINICAL ONCOLOGY*
Cappuzzo, F., Ligorio, C., Jaenne, P. A., Toschi, L., Rossi, E., Trisolini, R., Paioli, D., Holmes, A. J., Magrini, E., Finocchiaro, G., Bartolini, S., Cancellieri, A., Ciardiello, et al
2007; 25 (16): 2248–55
 - **MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling** *SCIENCE*
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J., Lindeman, N., Gale, C., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, et al
2007; 316 (5827): 1039–43
 - **Phase II clinical trial of chemotherapy-naive patients >= 70 years of age treated with erlotinib for advanced non-small-cell lung cancer** *JOURNAL OF CLINICAL ONCOLOGY*
Jackman, D. M., Yeap, B. Y., Lindeman, N. I., Fidias, P., Rabin, M. S., Temel, J., Skarin, A. T., Meyerson, M., Holmes, A. J., Borras, A. M., Freidlin, B., Ostler, P. A., Lucca, et al
2007; 25 (7): 760–66
 - **Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomenigeal metastases treated with high-dose gefitinib** *JOURNAL OF CLINICAL ONCOLOGY*
Jackman, D. M., Holmes, A. J., Lindeman, N., Wen, P. Y., Kesari, S., Borras, A. M., Bailey, C., de Jong, F., Jaenne, P. A., Johnson, B. E.
2006; 24 (27): 4517–20
 - **Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib** *CLINICAL CANCER RESEARCH*
Jackman, D. M., Yeap, B. Y., Sequist, L. V., Lindeman, N., Holmes, A. J., Joshi, V. A., Bell, D. W., Huberman, M. S., Halmos, B., Rabin, M. S., Haber, D. A., Lynch, T. J., Meyerson, et al
2006; 12 (13): 3908–14